P-Selectin as Predictor Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy by Suharti, C. et al.
15 
 
 
P-Selectin as Predictor Venous Thromboembolism in 
Cancer Patients Undergoing Chemotherapy 
 
C. SUHARTI*, SANTOSA, Eko Adhi PANGARSO, Budi SETIAWAN, Baringin de SAMAKTO 
 
Division Hematology-Medical Oncology, Department of Medicine, Faculty of Medicine Diponegoro 
University/ Dr. Kariadi Hospital, Semarang, Indonesia 
 
ABSTRACT 
Background: Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is the second-leading cause of death in patients with malignancy. P-
selectin, the member of the selectin family of cell adhesion molecules, is found in the alpha granules 
of platelets and the Weibel-Palade bodies of endothelial cells.  It is express on the cell surface on 
activation, mediates the adhesion of leukocytes, platelets, and cancer cells in inflammation, 
thrombosis, and cancer growth and metastasis. Recently, P-selectin has been investigated as a novel 
predictor for DVT. Objectives: To investigate the role of sP-selectin as predictors of DVT in cancer 
patients undergoing chemotherapy.  Patients and Methods: This prospective cohort study was 
conducted in Dr. Kariadi hospital, Semarang, Indonesia, on 40 newly diagnosed cancer patients. 
Venous blood samples were drawn prior and after initial chemotherapy, for sP-selectin measurement 
with ELISA method. These patients were observed for the possibility of developing VTE during three-
months period.  Results: DVT occurred in 5 (12.5%) patients after a median period of 8 weeks. The 
most frequent cancer type was colorectal cancer (45%) and cervical cancer (15%). The cut-off point sP-
selectin pre-and post- chemotherapy were 106,7 ng/ml and 111,7 ng/ml respectively. The median 
levels of sP-selectin in DVT patients pre-chemotherapy was 121.0ng/ml (IQR 107.5-230.6) and post-
chemotherapy was 204.4ng/ml (IQR 110.9-278.3). In other hand, the median levels of sP- selectin pre-
chemotherapy and post- chemotherapy in DVT negative patients were 82.0ng/ml (IQR 31.3-230.6) 
and 92.5 (IQR 40.9-278.3), respectively. With cut-off point sP-selectin level 111,7 ng/ml, the relative 
risk of DVT event was 8,7 (95% CI 1,017-74,39). Conclusion: In this study, high plasma levels of s 
P-selectin are predictive for venous thromboembolism in cancer patients undergoing chemotherapy. 
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Venous thromboembolism (VTE), consisting of 
deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is the second-leading cause of 
death in patients with malignancy. The risk for 
VTE increased in hospitalized cancer patient and 
in those on active therapy. VTE results in a 
requirement for long-term anticoagulation, risk of 
bleeding complications, risk of recurrent events 
even with anticoagulation, delay or 
discontinuation of chemotherapy, consumption of 
healthcare resources, and a potential impact on 
patient quality of life.(1)(2) 
The pathogenesis of VTE in cancer patients 
appears to be multifactorial. The most important 
clinical determinants for the risk of VTE are: (i) 
cancer-related factors (primary site, extensive 
disease, time interval from cancer diagnosis); (ii) 
patient-related factors (raised body mass index, 
reduced mobility, comorbidities, sepsis, previous 
VTE, abnormalities in blood counts); and (iii) 
treatment-related factors (chemotherapy, 
hormonal and biological therapy, surgery, 
indwelling catheters, erythropoietin stimulating 
agents).(3) 
Among tumor sites, the very high risk for 
thrombosis were pancreas and stomach, the high 
risk were lung, lymphoma, gynecologic, bladder 
and testicular; and the lower risk were breast and 
prostate cancer.(4) There also appears to be a 
time-dependent variation in the VTE risk. During 
the first 3 months after cancer diagnosis, patients 
are at highest risk of VTE.(5)(6) 
Virchow’s triad consisting of stasis, endothelial 
injury and hypercoagulability has long been 
known as the major risk factor predisposing 
patients to VTE. This model is particularly 
illustrative for cancer and thrombosis. Elevation 
in coagulation activation and thrombin 
generation (prothrombin fragment 1+2, 
thrombin-antithrombin complex, and D-dimer), 
alteration in fibrinolysis (plasmin-antiplasmin 
complexes, PAI-1), decreased inhibitors (protein 
C, protein S, antithrombin) and activated protein 
C resistance are considered as markers of 
hypercoagulability in cancer. Venous stasis in 
cancer may due to decreased patient mobility, 
extrinsic compression by tumor or node and 
venous invasion by tumor. Endothelial injury in 
cancer may as a result from tumor invasion, 
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surgery, radiation, central venous catheter and 
chemotherapy.(7)(8)  Recent advances in the 
epidemiology, pathophysiology and management 
of thrombosis in cancer patients.  
Several biomarkers have been identified as 
potentially predictive for VTE. Pre-chemotherapy 
elevation in leukocyte and platelet count and low 
haemoglobin levels are all predictive for 
chemotherapy associated VTE.(9)  Other 
biomarkers, including soluble P-selectin, 
prothrombin fragment 1,2, factor VIII, C reactive 
protein and D-dimers have been studied as well.    
P-selectin (CD62) is localized in the alpha 
granules of platelets and the Weibel-Palades 
bodies of endothelial cells, and belong to the 
selectin family of cell adhesion molecules. P-
selectin mediates binding to specific 
carbohydrate-containing ligands, like PSGL-1 (P-
selectin glycoprotein ligand-1) which is present on 
the majority of leukocytes and in smaller amounts 
of platelet. Soluble P-selectin (sP-selectin) is a 
circulating form of P-selectin, which results from 
shedding of the extracellular domain and 
maintains the requirements for ligand 
binding.(10) Plasma levels of sP-selectin are 
elevated in acute deep vein thrombosis. 
Furthermore, high levels of sP-selectin were 
associated with increased risk for recurrence of 
DVT(11)(12) and in cancer patients, high plasma 
levels of sP-selectin were predictive for VTE13. It 
is very interesting that cancer cells are able to 
enhance P-selectin expression on monocytes, 
macrophages, endothelial cells, and platelets.  In 
the other hand, cancer cells also express CD24 on 
their surface which was identified to be a receptor 
for P-selectin. The interaction between  P-selectin 
and CD24 on cancer cells allows their interaction 
with platelets, and their adherence to 
endothelium in the process of metastatic 
spread.(10) 
The aim of the study is to investigate the role 
of sP-selectin as predictive parameter for the 
occurrence of VTE in cancer patients undergoing 
chemotherapy. 
 
METHODS 
Study setting    
This cohort prospective study was performed 
in Dr. Kariadi hospital, the university hospital of 
Diponegoro University, Semarang, Indonesia. 
The research protocol was approved by the 
Review Board of the Dr. Kariadi hospital. Written 
informed consent was obtained from patients. 
 
Patients and data collection 
Between November 2016 and February 2017, 
40 consecutive patients with active cancers were 
enrolled in the study. All patients were informed 
about the details of the study in an individual 
interview.  The inclusion criteria for the study 
were as follows: (i) patients with newly diagnosed 
of cancer (ii) histological confirmation of the 
diagnosis (iii) age over 18 years (iv) willingness to 
participate and (v) written informed consent. 
Exclusion criteria were overt bacterial or viral 
infection within the last two weeks, venous or 
arterial thromboembolism within the last three 
months and continuous anticoagulation with 
vitamin K-antagonists or low molecular weight 
heparin (LMWH), and surgery or radiotherapy 
within the last two weeks. 
Patients underwent a structured interview on 
their medical history, and data on tumor site, 
tumor histology and tumor stage were 
documented. Patients were given detailed written 
information about symptoms of VTE and were 
asked to report immediately to our center, if such 
symptoms occurred. A blood sample for 
determination of laboratory parameters was 
drawn before and after initial chemotherapy. The 
observation period started at the time of blood 
sampling. Patients were contacted every month 
via telephone to get information about the clinical 
course of their disease regarding occurrence of 
VTE. Observation period ended after 3-mo nths 
period, or until the occurrence of VTE, death, loss 
of follow-up or withdrawal of consent (which one 
of these came first). 
  
Diagnosis of deep vein thrombosis  
Color duplex sonography was performed at the 
Division of Radiology of Dr. Kariadi Hspital, 
Semarang, Indonesia. Patients with clinically 
suspected DVT and the pretest probability (Well 
scores ≥ 2) were performed color duplex 
ultrasonography. To avoid investigator-related 
variations of the results, color duplex sonography 
was performed in each patient by the same 
investigator. Diagnosis VTE was established 
when patient presented symptoms of VTE and 
positive findings either in duplex sonography or 
venography.  
 
Blood sampling and laboratory analysis  
Venous blood specimens were collected by 
sterile and atraumatic antecubital venipuncture, 
and collected in in citrate vacutainer tubes SST 
5ml, containing 0.5ml of liquid anticoagulant. To 
obtain platelet-poor plasma, the citrated blood 
was centrifuged at 1000g (3000 rpm) for 15 min. 
Plasma aliquots were stored at-20 °C until they 
were assayed for the determination of sP-selectin 
plasma levels in series. Samples were coded prior 
to laboratory analysis. P-selectin levels were 
measured using a recombinant human P-selectin 
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Immunoassay/CD62P catalog number ADP3 
(R&D Systems, Inc. 614 McKinley Place NE, 
Minneapolis, MN 55413, USA) following the 
manufacturer´s instructions.  
Blood samples were scheduled to be drawn at 
the following time-points: (i) baseline, before 
initial chemotherapy, and (ii) the day after initial 
chemotherapy completely administrated. 
 
Statistical analysis  
Continuous variables were summarized with 
mean (SD) or medians (25th-75th percentile), 
whereas categorical data were described by 
absolute frequencies and percentages. The 
correlation between two continuous variables 
were evaluated with Spearman rank correlation 
coefficient.  Fisher exact test was performed if the 
number of cells with expected frequency less than 
5. Independent t-tests were done to compare 
numeric variables between DVT and non DVT 
patients. The assumption of normality test of the 
data was checked before the t-test. Mann-
Whitney were done when the data were not 
normally distributed. The cut-off-point of 
significance was p=0.05 with 95% confidence 
interval. The median follow-up time was 
calculated with the reverse Kaplan Meier method 
33. A log rank test was used to compare the time 
until first thrombosis in these two groups.  
 
RESULTS 
Between November 2016 and February 2017, 40 
patients with newly diagnosed cancer were 
enrolled in the study. One patient died before 
given chemotherapy on 6th weeks. DVT occurred 
in 5 (12.5%) patients after a median period of 8 
weeks. Positive findings in duplex sonography or 
venography established the diagnosis of DV 
  
Table 1. Clinical characteristics of patients. n=40 
Variable N % 
Age  
<41 
41-59 
>59 
 
11 
25 
4 
 
27.5 
62.5 
10 
Sex 
Male 
Female 
 
22 
18 
 
55 
45 
Body mass index 
Underweight  
Normal   
 
11 
29 
 
27.5 
72.5 
Site of cancer 
Rectal  
Colon  
Cervical 
Pancreas  
Lung  
Gaster  
Haematological  
Others 
 
10 
8 
6 
3 
2 
2 
2 
7 
 
25 
20 
15 
7.5 
5 
5 
5 
17.5 
Stage of cancer 
Localized  
Distance metastatic 
Unclassified 
 
23 
15 
2 
 
57.5 
37.5 
5 
The mean age of patients was 47±11. The most frequent cancer type was colorectal cancer (45%) 
and cervical cancer (15%). 
 
Plasma concentrations of sP-selectin in 
cancer patients with and without DVT 
The plasma concentration of sP-selectin in 
cancer patients without DVT, pre- and post-
chemotherapy administration (median, IQR) 
were: 82ng/ml, IQR (31.3-230.6) and 
92.5ng/ml, IQR (40.9-278.3), respectively. 
The plasma concentrations sP-selectin in 
cancer patients with DVT, before and after 
chemotherapy (median, IQR) were: 121.0 
ng/ml, IQR (107.5-230.6) and 204.4ng/ml, 
IQR (110.9-278.3), respectively. (Normal 
value sP-selectin: 0.99-47.7ng/ml). 
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Figure 1.The plasma concentrations of  sP-selectin levels pre-chemotherapyin 40 cancer patients 
with and without DVT. The difference is significant (p=0.041). Normal value sP-selectin: 0.99-
47.7ng/ml. 
 
 
Figure 2.The plasma concentrations of  sP-selectin levels post-chemotherapy in 40 cancer patients 
with and without DVT. The difference is significant (p=0.000). Normal value sP-selectin: 0.99-
47.7ng/ml. 
 
The cut-off point sP-selectin pre- and post- 
chemotherapy were 106,7 ng/ml and 111,7 
ng/ml respectively.  With the cut-off point P-
selectin level > 111,7 ng/ml, the relative  risk 
of DVT event was 8,7 (95% CI 1,017 – 74,39). 
(Table 2) 
 
Table 2. Risk Estimate for the DVT occurrence with cut-off plasma levels sP-
selectin111.7ng/ml in 39 cancer patients undergoing chemotherapy  
 Value  Lower (95% 
CI) 
Upper (95% 
CI) 
Relative risk for sP-selectine 
2(>111.7/≤111.7) 
12.000 1.078 133.603 
For cohort DVT = positive 8.700 1.017 74.390 
For cohort DVT = negative .725 .480 1.094 
N of valid cases 39*   
 
The relative risk for DVT for 39 cancer patients undergoing chemotherapy with plasma levels sP-
selectine >111.7ng/ml was 8.7 (95% CI 1.017-74.390). *one patient was died during the 6th week 
follow-up. 
 
  
P=0.041 
P=0.000 
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DISCUSSION 
In the present study, we investigate the 
role of sP-selectine as a novel predictor DVT 
in cancer patients undergoing chemotherapy. 
Our finding demonstrates that plasma levels 
sP-selectine >111.7ng/ml, the relative risk for 
DVT is 8.7 (95% CI 1.017-74.390). Therefore, 
it means that high levels of sP-selectin are 
predictor for DVT in cancer patients 
undergoing chemotherapy. 
Result from the Vienna CATS (Cancer And 
Thrombosis Study) demonstrates that 
elevated sP-selectin (cut-off level, 53.1ng/ml, 
75th percentile of study population) was a 
statistically significant risk factor for VTE 
after adjustment for age, sex, surgery, 
chemotherapy, and radiotherapy (hazard 
ratio=2.6, 95% confidence interval, 1.4-4.9, 
p=.003).(13)  
Our data indicate that, the levels of sP-
selectin were high in all cancer patients, 
either in DVT or non-DVT, and, either pre- or 
post-chemotherapy. Virchow’s triad (stasis, 
endothelial injury, and hypercoagulability) 
has long been used to illustrate the major risk 
factors predisposing patients to VTE. In our 
study, the increased levels of sP-selectin in 
all cancer patients reflected the 
hypercoagulability (prothrombotic) 
condition, which increased risk for 
thrombosis in cancer patients.   
Moreover, in all cancer patients, either 
withDVT or without DVT, the levels of sP-
selectin in post chemotherapy were higher 
than those in pre-chemotherapy, and the 
difference was significant. This finding 
indicated, that chemotherapy may increase 
the levels of sP-selectin, and therefore 
increase the risk for thrombosis. 
In a population-based study of patients 
with a new diagnosis of VTE, there was a 
significantly increased risk of VTE in those 
who were receiving chemotherapy [OR 6.5, 
CI(2.11-20)].(14) Our study, which involving 
plasma levels sP-selectine >111.7ng/ml as 
cut-off point, the RRwas 8.7 (95% CI 1.017-
74.390). Other study reported that 
chemotherapy increased the risk of VTE by 2-
fold to 6-fold, with doxorubicin containing 
regimens.(3) The mechanism behind the risk 
of thromboembolic events with chemotherapy 
treatments are poorly understood. Many of 
these chemotherapies induce vascular 
damage, either directly or indirectly, thereby 
promoting local activation of the coagulation 
process. A number of more recent reports 
have demonstrated the role of P-selectin in 
hemostasis and thrombosis, including the 
demonstration that overexpression of P-
selectin can induce a procoagulant state. 
One out of 40 patients died during follow-
up. The clinical presentation of this patient 
were shock and sudden death. This patient 
died possibly due to pulmonary embolism. 
In conclusion, our study demonstrated that: 
(i) high plasma levels of soluble P-selectin are 
predictive for venous thromboembolism in 
cancer patients; (ii) the levels of sP-selectin 
were high in cancer patients, and the levels 
in post-chemotherapy were significantly 
higher than those in pre-chemotherapy. 
Further studies are needed whether 
combination of high levels of sP-selectin and 
predictive model for calculating risk of 
chemotherapy associated thrombosis (e.g. 
Khorana predictive model) increase the 
benefit of prophylactic anticoagulation for 
cancer patients undergoing chemotherapy. 
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